Literature DB >> 3092349

Antibodies to Enterobacteriaceae in ankylosing spondylitis.

C G van Bohemen, A J Nabbe, H S Goei The, A J Dekker-Saeys, H C Zanen.   

Abstract

Serological studies on ankylosing spondylitis (AS; N = 82) show that although statistically more AS patients than controls (N = 24) may possess elevated serum titres to enterobacteria such as Salmonella, Shigella and Yersinia, this does not necessarily imply enterobacterial involvement in AS, as other groups without enteritis or arthropathies that frequent health care facilities (N = 72) may also display this phenomenon, presumably due to increased exposure. Moreover, an inventory of all detectable antibody reactivities to the separated cell envelope antigens of five enterobacterial species suspected of involvement in AS (notably Enterobacter, Klebsiella, Salmonella, Shigella and Yersinia) failed to reveal statistical associations with AS. This might be explained, assuming that the aetiology of AS entails a set of enterobacteria rather than a few individual species. It is proposed that serological studies on AS should be supported by additional information, e.g. that of the faecal carriage, and that these combined studies encompassing other enterobacteria, in addition to Klebsiella, might be fruitful.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092349     DOI: 10.3109/03009748609102080

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

Review 1.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  IgA antibodies against Klebsiella and other Gram-negative bacteria in ankylosing spondylitis and acute anterior uveitis.

Authors:  S H Sprenkels; E Van Kregten; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

3.  IgA antibodies in HLA-B27 associated acute anterior uveitis and ankylosing spondylitis.

Authors:  S H Sprenkels; J Uksila; R Vainionpää; P Toivanen; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

4.  Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.

Authors:  R Cooper; S M Fraser; R D Sturrock; C G Gemmell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

5.  Incidence of Yersinia enterocolitica antibodies in patients with inflammatory joint diseases.

Authors:  V Tamburrino; R Monno; M A Valenza; R Numo
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

6.  Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn's disease.

Authors:  S O'Mahony; N Anderson; G Nuki; A Ferguson
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

7.  Supplemental Anti Vegf A-Therapy Prevents Rebound Neovascularisation After Fine Needle Diathermy Treatment to Regress Pathological Corneal (LYMPH)Angiogenesis.

Authors:  Viet Nhat Hung Le; Yanhong Hou; Felix Bock; Claus Cursiefen
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.